Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Wan Xuan Selina Lim, Xue Fen Valerie Seah, Koh Cheng Thoon, Zhe Han
OBJECTIVES: Vancomycin 24-hour area under the curve over minimum inhibitory concentration (AUC/MIC) monitoring has been recommended over trough-based monitoring in pediatric patients. This study compared the proportion of target attainment between vancomycin AUC/MIC and trough-based methods, and identified risk factors for subtherapeutic initial extrapolated targets. METHODS: This was a retrospective, observational study conducted at KK Women's and Children's Hospital (KKH), Singapore...
2023: Journal of Pediatric Pharmacology and Therapeutics: JPPT: the Official Journal of PPAG
#22
JOURNAL ARTICLE
Jessica Le Blanc, Denis Projean, Sandra Savignac, Sophie Léveillé, Marie-Pier Ducas, Annie Brisebois-Boyer, Amélie Marsot
BACKGROUND AND OBJECTIVE: There is no consensus on the optimal vancomycin dose to achieve pharmacokinetic/pharmacodynamic (PK/PD) target in patients with hematologic cancer or in hematopoietic stem cell transplant (HSCT) recipients. A 24-h area under the concentration-time curve (AUC) >400 mg*h/L must be achieved early for successful treatment of severe methicillin-resistant Staphylococcus aureus (MRSA) infections. Current nomograms derived from general population data are not sufficiently accurate to allow AUC-based model-informed precision dosing...
December 21, 2023: Clinical Pharmacokinetics
#23
JOURNAL ARTICLE
Suhua She, Yulong Shen, Kun Luo, Xiaohai Zhang, Changjun Luo
BACKGROUND: Acute kidney injury (AKI) is prevalent in patients with intracerebral hemorrhage (ICH) and is associated with mortality. This study aimed to verify the predictive accuracy of different machine learning algorithms for AKI in patients with ICH using a large dataset. METHODS: A total of 1366 ICH patients received treatments between 2001 and 2012 from the Medical Information Mart for Intensive Care-III (MIMIC-III) database were identified based on the ICD-9 code: 431...
2023: Neuropsychiatric Disease and Treatment
#24
Yisroel Y Grabie, Stephanie Chain, Michael Xerras, Kelly Hong, Sadaf A Khan
Vancomycin, a potent glycopeptide antibiotic renowned for its efficacy against methicillin-resistant Staphylococcus aureus, also harbors the potential for adverse reactions. While its use is often associated with infusion-related events and nephrotoxicity, ototoxicity has emerged as a noteworthy but rare concern. This adverse effect, characterized by a spectrum of transient to permanent hearing loss or damage, typically surfaces in patients receiving excessive doses, those undergoing concomitant therapy with other ototoxic agents such as aminoglycosides, or individuals with baseline hearing impairment or renal dysfunction...
November 2023: Curēus
#25
JOURNAL ARTICLE
M Sreejisha, M Shalini Shenoy, M Suchitra Shenoy, B Dhanashree, M Chakrapani, K Gopalakrishna Bhat
OBJECTIVES: This study aimed to detect heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) among methicillin-resistant S. aureus (MRSA) isolated from healthcare-associated infections and identify staphylococcal cassette chromosome mec (SCC mec ) types. METHODS: This study was conducted from February 2019 to March 2020 and included patients admitted in 4 tertiary care hospitals in Karnataka, India. Isolation and identification of MRSA were done using standard bacteriological methods...
November 2023: Sultan Qaboos University Medical Journal
#26
JOURNAL ARTICLE
Venkata K Yellepeddi, Bryn Lindley, Emi Radetich, Shaun Kumar, Zubin Bhakta, Laurie Leclair, Madison Parrot, David C Young
Vancomycin is the first-line agent to treat pulmonary infections caused by methicillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis (PwCF). However, there is no consensus on vancomycin initial dosing in this population among health institutions, and there is a large variability in initial dosing across the United States. In this study, we characterized the pharmacokinetics (PK) of vancomycin in PwCF using a population PK approach. The clinical PK data to develop the population PK model were obtained from vancomycin therapeutic monitoring data from PwCF undergoing treatment for infections due to MRSA...
December 7, 2023: Antimicrobial Agents and Chemotherapy
#27
JOURNAL ARTICLE
Xin Cheng, Yaru Wang, Jingxin Ma, Liyan Ma, Wei Sun, Jianrong Su
Strain C1 was successfully isolated from an immunosuppressed patient with persistent bacteremia, who had not previously been exposed to glycopeptide antibiotics. This strain was found to be a heterogeneous vancomycin intermediate-resistant Staphylococcus aureus (hVISA). It is noteworthy that, following a brief period of vancomycin treatment, strains C6, C8, and C9, which were obtained from blood and other body parts, exhibited a significant reduction in heterogeneity as determined by population analysis profile-area under the curve (PAP-AUC) detection...
December 7, 2023: Brazilian Journal of Microbiology: [publication of the Brazilian Society for Microbiology]
#28
JOURNAL ARTICLE
Peijun Liu, Bangwei Zeng, Xiaoyan Wu, Feng Zheng, Yangmei Zhang, Xiaohua Liao
BACKGROUND: Enterococcus faecalis is a common cause of healthcare-associated infections. Its resistance to linezolid, the antibiotic of last resort for vancomycin-resistant enterococci, has become a growing threat in healthcare settings. METHODS: We analyzed the data of E. faecalis isolates from 26 medical institutions between 2018 and 2020 and performed univariate and multivariate logistic regression analyses to determine the independent predictors for linezolid-resistant E...
November 30, 2023: European Journal of Clinical Microbiology & Infectious Diseases
#29
JOURNAL ARTICLE
Zaid K Yousif, Jejo D Koola, Etienne Macedo, Jorge Cerda, Stuart L Goldstein, Rajasekara Chakravarthi, Andrew Lewington, David Selewski, Michael Zappitelli, Dinna Cruz, Ashita Tolwani, Melanie S Joy, Vivekanand Jha, Raja Ramachandran, Marlies Ostermann, Bhavna Pandya, Anjali Acharya, Patrick Brophy, Daniela Ponce, Julia Steinke, Josee Bouchard, Carlos E Irarrazabal, Romina Irarrazabal, Andrés Boltansky, David Askenazi, Nitin Kolhe, Rolando Claure-Del Granado, Nadine Benador, Clare Castledine, Andrew Davenport, Jonathan Barratt, Sunil Bhandari, Alyssa A Riley, T K Davis, Christopher Farmer, Michael Hogarth, Mark Thomas, Patrick T Murray, Cassianne Robinson-Cohen, Paola Nicoletti, Sucheta Vaingankar, Ravindra Mehta, Linda Awdishu
INTRODUCTION: Drug-induced acute kidney injury (DI-AKI) is a frequent adverse event. The identification of DI-AKI is challenged by competing etiologies, clinical heterogeneity among patients, and a lack of accurate diagnostic tools. Our research aims to describe the clinical characteristics and predictive variables of DI-AKI. METHODS: We analyzed data from the Drug-Induced Renal Injury Consortium (DIRECT) study (NCT02159209), an international, multicenter, observational cohort study of enriched clinically adjudicated DI-AKI cases...
November 2023: KI Reports
#30
JOURNAL ARTICLE
Hiroshi Sasano, Kazuhiko Hanada
PURPOSE: Enterococcal bacteremia is associated with high mortality and long-term hospitalization. Here, we aimed to investigate the clinical outcomes and evaluate the risk factors for mortality in adult patients treated with vancomycin (VCM) for vancomycin-susceptible Enterococcus faecium ( E. faecium ) bacteremia. METHODS: This is a retrospective, record-based study. The data were collected from inpatients at a single university hospital between January 2009 and December 2020...
October 29, 2023: Antibiotics
#31
JOURNAL ARTICLE
Claudia Sette, Marcello Mariani, Luca Grasselli, Alessio Mesini, Carolina Saffioti, Chiara Russo, Roberto Bandettini, Andrea Moscatelli, Luca A Ramenghi, Elio Castagnola
Bloodstream infections (BSI) from coagulase-negative-staphylococci (CoNS) are among the most frequent healthcare-related infections. Their treatment involves the use of vancomycin, a molecule whose optimal pharmacokinetic/pharmacodynamic (PK/PD) target for efficacy and safety is an area-under-curve/minimum inhibitory concentration (AUC/MIC) ratio ≥ 400 with AUC < 600. BSIs from CoNS in pediatric and neonatal intensive care unit that occurred at the Gaslini Institute over five years were evaluated to investigate the efficacy of vancomycin therapy in terms of achieving the desired PK/PD target and determining whether any variables interfere with the achievement of this target...
October 26, 2023: Antibiotics
#32
JOURNAL ARTICLE
Ronaldo Morales, Vanessa D'Amaro Juodinis, Daniela Carla de Souza, Silvia Regina Cavani Jorge Santos
INTRODUCTION: Vancomycin is widely prescribed to treat or prevent Gram-positive infections in pediatric liver transplant recipients. The objective of this prospective cohort study is to describe vancomycin pharmacokinetics and to evaluate the therapeutic target attainment after initial dose regimen. MATERIALS AND METHODS: Patients with previous renal injury were excluded. Vancomycin therapy started with 40‒60 mg/kg/day. The pharmacokinetic parameters were assessed using two steady-state blood samples and the first-order kinetic equations...
November 14, 2023: Brazilian Journal of Infectious Diseases
#33
JOURNAL ARTICLE
Hedieh Tazerouni, Zohre Labbani-Motlagh, Shahideh Amini, Bita Shahrami, Sayed Mahmoud Sajjadi-Jazi, Shirin Afhami, Kheirollah Gholami, Kourosh Sadeghi
PURPOSE: This study aimed to compare individual pharmacokinetic (PK) parameters of vancomycin with predicted values from five population PK models in patients with diabetic foot infections (DFIs). METHODS: Patients with a diagnosis of DFI and an estimated glomerular filtration rate (eGFR) ≥ 30 mL/min were included in the study. Individual PK data was carried on by collecting three vancomycin serum concentrations in a steady-state condition. Five published population-based nomograms were assumed to predict PK parameters...
December 2023: Journal of Diabetes and Metabolic Disorders
#34
JOURNAL ARTICLE
Tan Zhang, Elke H J Krekels, Cornelis Smit, Eric P A van Dongen, Roger J M Brüggemann, Catherijne A J Knibbe
BACKGROUND AND OBJECTIVE: The latest vancomycin guideline recommends area under the curve (AUC)-targeted dosing and monitoring for efficacy and safety. However, guidelines for AUC-targeted starting dosing in patients with obesity and/or renal insufficiency are currently lacking. This study quantifies the pharmacokinetics (PK) of vancomycin in this population and provides AUC-targeted dosing recommendations. METHODS: Vancomycin concentrations (n = 1188) from therapeutic drug monitoring of 210 overweight and obese patients with varying degrees of renal (dys)function from the ward (74...
November 16, 2023: Clinical Pharmacokinetics
#35
JOURNAL ARTICLE
Naoko Kanazawa, Akari Shigemi, Nao Amadatsu, Kotaro Arimura, Shohei Shimono, Kazutaka Oda, Victor Tuan Giam Chuang, Kazuaki Matsumoto, Hideki Kawamura, Hideyuki Terazono
OBJECTIVES: In recent years, Vancomycin (VCM) dosing design using area under the concentration-time curve (AUC) has been recommended as a measure of efficacy and safety, but there are fewer reports on pediatric patients than on adults. In this study, we evaluated the threshold of AUC for AKI occurrence in pediatric patients and investigated the factors that contribute to the occurrence of AKI. METHODS: Pediatric patients aged 1-15 years on VCM treatment who underwent TDM at Kagoshima University Hospital from April 2016 to March 2022 were included in the computation of AUC using pediatric population pharmacokinetic parameters...
November 6, 2023: Journal of Infection and Chemotherapy: Official Journal of the Japan Society of Chemotherapy
#36
JOURNAL ARTICLE
Tomoyuki Ishigo, Satoshi Fujii, Yuta Ibe, Tomohiro Aigami, Keita Nakano, Masahide Fukudo, Hiroaki Yoshida, Hiroaki Tanaka, Fumiya Ebihara, Takumi Maruyama, Yukihiro Hamada, Ayako Suzuki, Hisato Fujihara, Fumihiro Yamaguchi, Masaru Samura, Fumio Nagumo, Toshiaki Komatsu, Atsushi Tomizawa, Akitoshi Takuma, Hiroaki Chiba, Yoshifumi Nishi, Yuki Enoki, Kazuaki Taguchi, Kazuaki Matsumoto
INTRODUCTION: In therapeutic drug monitoring (TDM) of vancomycin (VCM), the area under the concentration-time curve (AUC) is related to the clinical efficacy and toxicity. Therefore, herein, we examined the factors associated with achieving the target AUC at follow-up and developed a decision flowchart for achieving the target AUC in critically ill patients. METHODS: This multicenter retrospective observational study was conducted at eight hospitals. We retrospectively analyzed data from patients who had received VCM in the intensive care unit from January 2020 to December 2022...
November 2, 2023: Journal of Infection and Chemotherapy: Official Journal of the Japan Society of Chemotherapy
#37
JOURNAL ARTICLE
Yaxin Fan, Kaiting Zhang, Mengting Chen, Nanyang Li, Xiaofen Liu, Minjie Yang, Xiaoyu Liang, Jufang Wu, Beining Guo, Huajun Zheng, Yongqiang Zhu, Fengying Zhang, Jingqing Hang, Huifang Zhang, Ruilan Wang, Qing Yuan, Xiaolian Song, Shengbin Wu, Bo Shen, Jing Zhang
This study compared the impact of sequence type 5 (ST5) and ST764, on the efficacy of vancomycin treatment in methicillin-resistant Staphylococcus aureus (MRSA) infections. From July 2012 to June 2020, a prospective observational study was conducted in five hospitals in China, enrolling 90 patients with MRSA infections, including 44 patients with ST5-MRSA and 46 patients with ST764-MRSA infections. All strains were subjected to minimal inhibitory concentration (MIC) determination, biofilm expression, heterogeneous vancomycin-intermediate S...
October 31, 2023: MSphere
#38
JOURNAL ARTICLE
Diari Gilliam, Dominic Acosta, Martha L Carvour, Carla Walraven
PURPOSE: Vancomycin is commonly administered as an intermittent infusion (IIV), although vancomycin's stability at room temperature permits administration continuously over 24 h (CIV). At our institution, CIV has been the preferred infusion method for over 20 years due to ease of administration and simplicity of therapeutic drug monitoring. The purpose of this study was to examine the outcomes associated with IIV compared to CIV. METHODS: This was a retrospective study of patients who received vancomycin for MRSA bacteremia...
October 28, 2023: European Journal of Clinical Pharmacology
#39
JOURNAL ARTICLE
Yuto Yamada, Takashi Niwa, Yurie Ono, Shoya Yamada, Kyoko Niwa, Moeka Yasue, Taishi Yamamoto, Kazuyuki Sumi, Manami Otsubo, Ryo Kobayashi, Akio Suzuki
OBJECTIVES: Although use of AUC-guided vancomycin dosing was recommended in the revised 2020 consensus guideline, collection of multiple vancomycin serum samples to calculate AUC may cause clinical complications. AUC calculated from trough-only data (one-point AUC-guided dosing) has not been sufficiently validated. The aim of the present study was to compare the incidence of nephrotoxicity following the change from trough-guided to one-point AUC-guided dosing. METHODS: We conducted a single-centre, prospective cohort study to compare the incidence of nephrotoxicity between a trough-guided dosing group and one-point AUC-guided dosing group...
December 1, 2023: Journal of Antimicrobial Chemotherapy
#40
JOURNAL ARTICLE
Sukyong Yoon, Jinju Guk, Sang-Guk Lee, Dongwoo Chae, Jeong-Ho Kim, Kyungsoo Park
Introduction: While vancomycin remains a widely prescribed antibiotic, it can cause ototoxicity and nephrotoxicity, both of which are concentration-associated. Overtreatment can occur when the treatment lasts for an unnecessarily long time. Using a model-informed precision dosing scheme, this study aims to develop a population pharmacokinetic (PK) and pharmacodynamic (PD) model for vancomycin to determine the optimal dosage regimen and treatment duration in order to avoid drug-induced toxicity. Methods: The data were obtained from electronic medical records of 542 patients, including 40 children, and were analyzed using NONMEM software...
2023: Frontiers in Pharmacology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
